The severity of tau pathology, in particular, has been implicated as a major predictive factor for the extent of cognitive impairment, making it a promising therapeutic target for AD (Arriagada et al., 1992; Bejanin et al., 2017; Harrison et al., 2019; La Joie et al., 2020). The gene discussed is MAPT; the disease is Cognitive impairment.